神経膠腫治療市場：神経膠腫の種類、治療タイプ、エンドユーザー、流通チャネル別-2025-2030年の世界予測

神経膠腫治療市場は、2023年に49億5,000万米ドルと評価され、2024年には52億9,000万米ドルに達すると予測され、CAGR 7.43％で成長し、2030年には81億8,000万米ドルに達すると予測されています。

神経膠腫治療は、グリア細胞から発生する脳腫瘍の一種であるグリオーマの管理を目的とした包括的な方法論と治療法を指します。神経膠腫治療の必要性は、これらの腫瘍の攻撃的な性質によって強調されており、外科的介入や放射線療法から最先端の免疫療法や標的薬に至る革新的なソリューションが必要とされています。適用範囲は、病院、専門的ながん治療センター、個別化された在宅医療環境にまで及び、異なる病期にわたる多様な患者のニーズに対応しています。主なエンドユースセグメントには、ヘルスケアプロバイダーや、有効な治療法の開発と提供に注力する製薬会社などが含まれます。市場の成長は、脳腫瘍の有病率の増加、医療技術の進歩、がん研究を促進する政府の取り組みなど、いくつかの要因の影響を受けています。さらに、進行中の臨床試験や早期診断に対する意識の高まりは、技術革新の大きなチャンスとなります。企業は、バイオマーカー探索の研究や非侵襲的治療法の開発に投資することで、こうした可能性を活用することができます。しかし、市場の拡大は、治療費の高騰、規制の複雑さ、新興地域における高度な治療法の限定的な利用可能性といった課題に直面しています。競合情勢は急速な技術進歩によって形成されており、企業は研究開発を優先し、戦略的パートナーシップを築くことが不可欠です。技術革新が最も期待される分野としては、個別化医療のアプローチ、診断ツールへの人工知能の統合、患者管理のための遠隔医療の拡大などが挙げられます。市場競争と治療プロトコルの絶え間ない進化を特徴とする市場力学はダイナミックです。成功を目指す企業は、製品パイプラインの拡大、研究機関との協力関係の強化、未開拓市場の開拓に注力し、成長を維持しながら市場での差別化を図る必要があります。

市場力学：急速に進化する神経膠腫治療市場の主要市場インサイトを公開

神経膠腫治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 神経膠腫の世界の有病率の増加
  • 神経膠腫治療に対する改革と支援イニシアティブ
• 市場抑制要因
  • 併用治療の高コスト
• 市場機会
  • 精密医療技術の進歩
  • 神経膠腫の新規治療法の発見を目指した共同研究開発の取り組み
• 市場の課題
  • 現在の治療法の限られた有効性と副作用

ポーターのファイブフォース：神経膠腫治療市場をナビゲートする戦略的ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経膠腫治療市場における外部からの影響の把握

外部マクロ環境要因は、神経膠腫治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析神経膠腫治療市場における競合情勢の把握

神経膠腫治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス神経膠腫治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経膠腫治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨神経膠腫治療市場における成功への道筋を描く

神経膠腫治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 神経膠腫の罹患率は世界的に増加している
    • 神経膠腫治療の改革と支援の取り組み
  • 抑制要因
    • 併用治療のコストが高い
  • 機会
    • 精密医療技術の進歩
    • 神経膠腫の新たな治療法の発見を目指した共同研究開発
  • 課題
    • 現在の治療法の有効性と副作用は限られている
• 市場セグメンテーション分析
  • 治療の種類：広範囲に及ぶ悪性腫瘍に対する放射線療法は、その有効性から好まれる傾向が高まっています。
  • エンドユーザー：神経膠腫治療の発展と新しい治療戦略の開発に積極的に取り組んでいる調査機関
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 神経膠腫治療市場神経膠腫の種類別

• 高悪性度神経膠腫
• 低悪性度神経膠腫

第7章 神経膠腫治療市場治療の種類別

• 化学療法
• 免疫療法
• 放射線治療
• 標的療法

第8章 神経膠腫治療市場：エンドユーザー別

• 病院
• 調査機関
• 専門クリニック

第9章 神経膠腫治療市場：流通チャネル別

• 病院薬局
• 地元の薬局
• オンライン薬局

第10章 南北アメリカの神経膠腫治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の神経膠腫治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの神経膠腫治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • TLX101-CDx PETイメージング剤による神経膠腫の特性評価と治療の進歩
  • MimiVax, Inc.、グリオーブラストーマ治療におけるSurVaxMの発展に向けた戦略的投資を確保
  • Rigel Pharmaceuticals, Inc.とCONNECTが協力し、革新的な臨床試験を通じて小児用高グレード神経膠腫治療を推進
  • サーモフィッシャーとUCSFが腫瘍および希少疾患向けの先進的細胞治療薬の製造で提携
• 戦略分析と提言

企業一覧

• Amgen Inc.
• Azurity Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Emcure Pharmaceuticals Ltd.
• F. Hoffmann-La Roche Ltd
• Intas Pharmaceuticals Ltd.
• Karyopharm Therapeutics Inc.
• Mayo Clinic
• Merck & Co Inc.
• MimiVax, Inc.
• Pfizer Inc.
• Rigel Pharmaceuticals Inc.
• Sumitomo Dainippon Pharma Oncology Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. GLIOMA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. GLIOMA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GLIOMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GLIOMA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH-GRADE GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW-GRADE GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOCAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. CANADA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 37. CANADA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. CANADA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CHINA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 59. CHINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. CHINA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. INDIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 63. INDIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. ITALY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 132. ITALY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. ITALY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. POLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 148. POLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. POLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. QATAR GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 152. QATAR GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. QATAR GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Glioma Treatment Market was valued at USD 4.95 billion in 2023, expected to reach USD 5.29 billion in 2024, and is projected to grow at a CAGR of 7.43%, to USD 8.18 billion by 2030.

Glioma treatment refers to the comprehensive methodologies and therapies aimed at managing gliomas, a type of brain tumor arising from glial cells. The necessity for glioma treatment is underscored by the aggressive nature of these tumors, necessitating innovative solutions that can range from surgical interventions and radiation therapy to cutting-edge immunotherapies and targeted drugs. The scope of application extends to hospitals, specialized cancer treatment centers, and personalized home care settings, catering to diverse patient needs across different stages of the disease. Key end-use segments include healthcare providers and pharmaceutical companies focusing on the development and delivery of efficacious therapies. Market growth is influenced by several factors, including increasing prevalence of brain tumors, advances in medical technology, and government initiatives promoting cancer research. Moreover, ongoing clinical trials and heightened awareness about early diagnosis present significant opportunities for innovation. Companies can capitalize on these potentials by investing in research for biomarker discovery and development of non-invasive therapeutic options. However, market expansion faces challenges such as high treatment costs, regulatory complexities, and limited availability of advanced therapies in emerging regions. The competitive landscape is shaped by rapid technological advancements, making it imperative for businesses to prioritize R&D and forge strategic partnerships. Areas with the most promise for innovation include personalized medicine approaches, integration of artificial intelligence in diagnostic tools, and expansion of telemedicine for patient management. The glioma treatment market is dynamic, characterized by fierce competition and the constant evolution of therapeutic protocols. Firms looking to thrive should focus on expanding their product pipelines, enhancing collaboration with research bodies, and tapping into underserved markets to sustain growth and achieve significant market differentiation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glioma Treatment Market

The Glioma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of gliomas globally
  • Reforms and support initiatives for glioma treatment
• Market Restraints
  • High cost of combination treatment
• Market Opportunities
  • Advancements in precision medicine technologies
  • Collaborative R&D efforts aimed at discovering novel therapies for glioma
• Market Challenges
  • Limited efficacy and side effects of current treatments

Porter's Five Forces: A Strategic Tool for Navigating the Glioma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glioma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glioma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glioma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glioma Treatment Market

A detailed market share analysis in the Glioma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glioma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glioma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glioma Treatment Market

A strategic analysis of the Glioma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glioma Treatment Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Azurity Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd, Intas Pharmaceuticals Ltd., Karyopharm Therapeutics Inc., Mayo Clinic, Merck & Co Inc., MimiVax, Inc., Pfizer Inc., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Glioma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type of Glioma, market is studied across High-grade Gliomas and Low-grade Gliomas.
• Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy.
• Based on End-user, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Local Pharmacies, and Online Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of gliomas globally
    • 5.1.1.2. Reforms and support initiatives for glioma treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of combination treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in precision medicine technologies
    • 5.1.3.2. Collaborative R&D efforts aimed at discovering novel therapies for glioma
  • 5.1.4. Challenges
    • 5.1.4.1. Limited efficacy and side effects of current treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Growing preference for radiation therapy for widespread and aggressive tumors due to its efficacy
  • 5.2.2. End-user: Research institutes actively working on advancing glioma treatment and developing new therapeutic strategies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Glioma Treatment Market, by Type of Glioma

• 6.1. Introduction
• 6.2. High-grade Gliomas
• 6.3. Low-grade Gliomas

7. Glioma Treatment Market, by Treatment Type

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Immunotherapy
• 7.4. Radiation Therapy
• 7.5. Targeted Therapy

8. Glioma Treatment Market, by End-user

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Research Institutes
• 8.4. Specialty Clinics

9. Glioma Treatment Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Local Pharmacies
• 9.4. Online Pharmacies

10. Americas Glioma Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Glioma Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Glioma Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Advancements in Glioma Characterization and Treatment Through TLX101-CDx PET Imaging Agent
  • 13.3.2. MimiVax, Inc. Secures Strategic Investments to Advance SurVaxM in Glioblastoma Treatment
  • 13.3.3. Rigel Pharmaceuticals, Inc. and CONNECT Join Forces to Advance Pediatric High-Grade Glioma Treatment Through Innovative Clinical Trial
  • 13.3.4. Thermo Fisher and UCSF Collaborate on Advanced Cell Therapies Manufacturing for Oncological and Rare Diseases
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Azurity Pharmaceuticals, Inc.
• 3. Bristol-Myers Squibb Company
• 4. Emcure Pharmaceuticals Ltd.
• 5. F. Hoffmann-La Roche Ltd
• 6. Intas Pharmaceuticals Ltd.
• 7. Karyopharm Therapeutics Inc.
• 8. Mayo Clinic
• 9. Merck & Co Inc.
• 10. MimiVax, Inc.
• 11. Pfizer Inc.
• 12. Rigel Pharmaceuticals Inc.
• 13. Sumitomo Dainippon Pharma Oncology Inc.
• 14. Sun Pharmaceutical Industries Ltd.
• 15. Teva Pharmaceuticals Industries Ltd.
• 16. Thermo Fisher Scientific Inc.